Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin 287 vs Glargine in T2D
NCT03922750Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- May 2019
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of insulin icodec in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Percentage of Time in Target Range 3.9-10.0 mmol/L (70-180 mg/dL) at Week 16. Started May 2019; status: completed.
02
Drugs
insulin icodec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03922750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03922750.